Monoamine Oxidase Inhibitor Activity, Postprandial Blood Glucose, Prolactin Levels
Conditions
Brief summary
The current study uses a double-blind, placebo-controlled, randomised cross- over design to assess the pharmacodynamics of the platelet MAO-B inhibition, plasma prolactin levels and blood glucose levels after consumption of a single serve of 'Blackadder' blackcurrant juice.
Detailed description
There is emerging evidence which supports health benefits of consuming blackcurrant fruit, including improvements to cognitive performance, modulation of blood flow, regulation of blood glucose and inhibition of enzymes underpinning normal cognitive function. Of particular relevance is our previous demonstration of inhibition of MAO-A and B after consumption of a New Zealand 'Blackadder' blackcurrant juice drink in man. In an attempt to establish a therapeutic window on which future nutritional interventions can be based, the current study will assess the pharmacodynamics of MAO-B inhibition, plasma prolactin levels and venous blood glucose profile following consumption of the 'Blackadder' blackcurrant juice. The trial will utilise a 500mg dose of the 'Blackadder' juice (equivalent to \ 100g of fresh fruit) which was shown to have MAO inhibitory effects in our previous report and effects will be measured in a cohort of healthy male adults.
Interventions
DIETARY_SUPPLEMENTBlackadder Juice
OTHERPlacebo
Sponsors
Plant & food Research Ltd
Northumbria University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy * Male * Aged 18-35 * Non- smoker * No history of metabolic disease
Exclusion criteria
* Diagnosis of blood-borne disease * Diagnosed history of any psychiatric disorder * Aged under 18 or over 35 years * BMI above 30 kg/m2 or below 17 kg/m2, * Diagnosis of diabetes or current use of prescription or over-the-counter drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline Monoamine Oxidase B - Activity | 15, 30, 45 60, 100, 120, 150, 180 and 240 minutes and 24h post dose. | Platelet monamine oxidase- B activity as measured by the Invitrogen amplex red assay |
| Change from baseline peripheral prolactin levels | 15, 30, 45 60, 100, 120, 150, 180 and 240 minutes and 24h post dose. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline postprandial blood glucose | 15, 30, 45 60, 100, 120, 150, 180 and 240 minutes and 24h post dose. |
Outcome results
None listed